疟原虫有性生殖传播阻断疫苗的研究进展

Research advances on transmission-blocking vaccines targeting Plasmodium sexual stage

疟疾仍是一项重大的全球卫生挑战。现阶段由于药物和相关技术的应用,一定程度上减少了疾病的负担,但发病率和死亡率仍然非常高。随着耐药性的广泛出现,亟需探索和研制新的防疟根本策略,有效控制和阻断疟疾的传播。针对有性生殖阶段的传播阻断疫苗(TBV)是一个很好的选择,其旨在控制疟原虫从人类宿主传播到蚊媒媒介。TBV的研制受到了国内外研究者的重视,被认为是防治疟疾的新技术之一。本文总结了TBV的研究和开发,以及候选抗原的发现和进展,为TBV的进一步研究提供理论参考。

Malaria remains a major global health challenge. At present, due to the application of drugs and related technologies, the burden of disease has been reduced to a certain extent, but morbidity and mortality remain very high. With the widespread emergence of drug resistance, it is urgent to explore and develop new anti-malarial strategies to effectively control and block the spread of malaria. The transmission-blocking vaccine(TBV), which targets the sexual stage, is a good option to control the transmission of Plasmodium from human hosts to mosquito vectors. The development of TBV has attracted attention domestically and internationally. It is considered to be one of the new technologies for malaria control. This article summarizes the research and development of TBV, as well as the discovery and progress of candidate antigens, and provides a theoretical reference for further research on TBV.